Phospho-TGFBR2 (Ser225/250) Antibody

What is the specificity of Phospho-TGFBR2 (Ser225/250) antibody and how does it differ from general TGFBR2 antibodies?

Phospho-TGFBR2 (Ser225/250) antibody specifically recognizes the transforming growth factor beta receptor II protein only when it is phosphorylated at serine residue 225. This phosphorylation site is located within a functionally significant region (amino acids 191-240) of the receptor. Unlike general TGFBR2 antibodies that detect the receptor regardless of its phosphorylation state, this specific antibody enables researchers to investigate the active signaling form of the receptor. The antibody is typically produced using a synthesized peptide derived from human TGF beta Receptor II surrounding the phosphorylation site of Ser225/250 .

When designing experiments, researchers should consider that:

• The antibody's specificity must be validated through phospho-ELISA experiments comparing phosphopeptide versus non-phosphopeptide binding

• Immunohistochemistry applications should include appropriate phosphopeptide blocking controls

• Storage conditions (4°C short term; -20°C long term in aliquots) significantly impact antibody performance and specificity

The critical distinction between phospho-specific and general TGFBR2 antibodies lies in their ability to distinguish between inactive and actively signaling receptor populations, allowing for more precise analysis of TGF-β pathway activation states in experimental systems.

How should I design experiments to effectively use Phospho-TGFBR2 (Ser225/250) antibody in signaling pathway analysis?

For effective signaling pathway analysis with Phospho-TGFBR2 (Ser225/250) antibody, experimental design should incorporate the following methodological considerations:

• Treatment conditions: Include positive controls using known TGF-β pathway activators (e.g., exogenous TGF-β1/2/3) and negative controls using pathway inhibitors (e.g., TGF-β receptor kinase inhibitors).

• Time-course analysis: Design experiments with multiple time points (5-60 minutes for acute responses; 1-24 hours for secondary responses) to capture the dynamic phosphorylation events.

• Complementary phosphorylation sites: Consider parallel analysis of multiple TGFBR2 phosphorylation sites as well as downstream substrates like SMAD proteins to build a comprehensive signaling profile.

• Validation approach:

  • Western blotting with phospho-specific antibodies alongside total TGFBR2 antibodies

  • Immunoprecipitation followed by phospho-specific detection

  • Phospho-flow cytometry for cell-by-cell analysis

  • Immunofluorescence to analyze spatial distribution of phosphorylated receptors

• Functional correlation: Design parallel experiments measuring biological outcomes (e.g., gene expression changes, cell proliferation, migration) to correlate phosphorylation status with functional consequences .

When investigating TGF-β signaling in glioblastoma cells, researchers have successfully integrated network analysis with quantitative phosphoproteomics to identify key signaling pathways influenced by TGFBR2 activity. This approach revealed that TGFBR2-mediated signaling affects stem cell-like characteristics in these cells .

What are the optimal sample preparation protocols for preserving TGFBR2 phosphorylation status?

Preserving phosphorylation status during sample preparation is critical for accurate analysis with Phospho-TGFBR2 (Ser225/250) antibodies. The following protocol optimizations are essential:

• Immediate sample processing:

  • Process tissue samples immediately after collection or flash-freeze in liquid nitrogen

  • For cell culture, rapid lysis following stimulation is crucial as phosphorylation can be transient

  • Avoid repeated freeze-thaw cycles of protein samples which can reduce phospho-epitope integrity

• Phosphatase inhibitor cocktails:

  • Include both serine/threonine and tyrosine phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate, and sodium pyrophosphate)

  • Add protease inhibitors to prevent degradation of the receptor protein

  • Maintain cold temperature (4°C) throughout sample processing

• Buffer composition:

  • Use RIPA or NP-40-based lysis buffers with pH 7.4

  • Include 1-5 mM EDTA to chelate metal ions that can activate phosphatases

  • Avoid detergents that may interfere with phospho-epitope recognition

• Storage conditions:

  • Store antibody at 4°C short term or -20°C long term in aliquots to avoid freeze-thaw cycles

  • For protein lysates, add 50% glycerol for prolonged storage at -20°C

  • For fixed tissue samples, maintain in appropriate fixatives at recommended temperatures

The efficacy of phospho-specific antibodies is highly dependent on proper sample preparation. In research involving TGFBR2 phosphorylation in various disease models, inadequate phosphatase inhibition has been identified as a primary cause of inconsistent results and false-negative findings.

How can I distinguish between TGFBR2 auto-phosphorylation and trans-phosphorylation by other kinases?

Distinguishing between auto-phosphorylation and trans-phosphorylation of TGFBR2 requires sophisticated experimental approaches:

• In vitro kinase assays:

  • Purify TGFBR2 protein and perform in vitro kinase assays with and without ATP

  • Include catalytically inactive TGFBR2 mutants (e.g., K277R) that cannot auto-phosphorylate

  • Compare phosphorylation patterns using Phospho-TGFBR2 (Ser225/250) antibody detection

• Pharmacological inhibitor approach:

  • Use selective TGFBR2 kinase inhibitors to block auto-phosphorylation

  • Apply broad spectrum kinase inhibitors to identify potential upstream kinases

  • Quantify changes in Ser225/250 phosphorylation under these conditions

• Genetic manipulation strategies:

  • Express truncated TGFBR2 domains lacking the kinase domain but retaining Ser225/250

  • Use CRISPR/Cas9 to generate phospho-deficient mutants (S225A/S250A)

  • Compare phosphorylation patterns in cells expressing wild-type versus kinase-dead TGFBR2

• Mass spectrometry analysis:

  • Identify specific phosphorylation patterns that distinguish auto- vs. trans-phosphorylation

  • Analyze phosphopeptide signatures under various stimulation conditions

  • Quantify stoichiometry of phosphorylation at multiple sites

Research has demonstrated that in signaling cascades involving TGFBR2, certain phosphorylation events occur in a ligand-dependent manner while others represent constitutive phosphorylation. When investigating TGF-β signaling in glioblastoma cells, researchers have successfully used kinase prediction algorithms combined with phosphoproteomic data to distinguish between these phosphorylation mechanisms .

What are the recommended approaches for multiplexed analysis of phospho-TGFBR2 with other phosphorylated proteins in the TGF-β pathway?

Multiplexed analysis of phospho-TGFBR2 with other phosphorylated proteins in the TGF-β pathway requires sophisticated methodological approaches:

• Multiplex immunoassay platforms:

  • Utilize Luminex or Meso Scale Discovery platforms with validated antibody pairs

  • Combine Phospho-TGFBR2 (Ser225/250) detection with other key phospho-proteins (pSMAD2/3, pMAPK, pAKT)

  • Validate antibody specificity to prevent cross-reactivity in multiplexed formats

• Mass spectrometry-based phosphoproteomics:

  • Employ TiO2 or IMAC enrichment of phosphopeptides from cell lysates

  • Use SILAC, TMT, or label-free quantification for comparative analysis

  • Develop targeted SRM/MRM assays for specific phosphosites in the TGF-β pathway

• Sequential immunoprecipitation strategy:

  • First IP with Phospho-TGFBR2 (Ser225/250) antibody

  • Elute and perform secondary IP with antibodies against potential interacting proteins

  • Analyze phosphorylation status of co-precipitated proteins

• Spatial analysis using multiplexed imaging:

  • Apply sequential immunofluorescence or mass cytometry (CyTOF)

  • Use spectral unmixing algorithms to distinguish multiple fluorophores

  • Quantify co-localization of phosphorylated proteins at subcellular resolution

The importance of this approach is exemplified in research on glioblastoma cells, where the integration of phosphoproteomics with computational predictions identified functional connections between TGFBR2 phosphorylation and key downstream effectors. This approach revealed that inactivation of TGFBR2 led to increased self-renewal properties in glioblastoma cells, suggesting its role as a regulator of stem cell-like characteristics .

How can I validate the functional significance of TGFBR2 Ser225/250 phosphorylation in my experimental system?

Validating the functional significance of TGFBR2 Ser225/250 phosphorylation requires a multi-faceted experimental approach:

• Site-directed mutagenesis:

  • Generate phospho-deficient (S225A/S250A) and phospho-mimetic (S225D/S250D) TGFBR2 mutants

  • Express these constructs in TGFBR2-null or knockdown cells

  • Compare phenotypic outcomes and signaling responses between mutants

• Temporal analysis of phosphorylation:

  • Perform time-course experiments following TGF-β stimulation

  • Correlate Ser225/250 phosphorylation kinetics with downstream signaling events

  • Use phosphorylation-state specific antibodies at each time point

• Functional rescue experiments:

  • Inhibit endogenous TGFBR2 through genetic or pharmacological approaches

  • Introduce wild-type or mutant receptors to assess rescue capability

  • Quantify restoration of TGF-β-dependent cellular responses

• Protein-protein interaction studies:

  • Perform co-immunoprecipitation with Phospho-TGFBR2 (Ser225/250) antibody

  • Identify differential binding partners between phosphorylated and non-phosphorylated receptor

  • Validate key interactions through complementary methods (proximity ligation assay, FRET)

Research on glioblastoma cells has demonstrated that TGFBR2-mediated signaling plays a crucial role in stem cell-like properties. Experimental validation through signaling perturbation using specific inhibitors confirmed that TGFBR2 might be critically involved in promoting reduction of stem cell-like properties in glioblastoma cells . Similar approaches can be applied to investigate the specific role of Ser225/250 phosphorylation in various biological contexts.

How does TGFBR2 phosphorylation status correlate with cancer progression and therapy resistance?

The phosphorylation status of TGFBR2, particularly at Ser225/250, demonstrates significant correlations with cancer progression and therapy resistance across multiple tumor types:

• Altered phosphorylation in tumor samples:

  • Phospho-TGFBR2 (Ser225/250) levels are frequently dysregulated in glioblastoma tissues

  • Immunohistochemistry analysis of human brain tissues has revealed specific staining patterns that can be blocked with phospho-peptides, indicating specificity of the phosphorylation signal

  • TGFBR2-mediated signaling has been identified as a key regulator of stem cell-like properties in glioblastoma cells

• Correlation with therapeutic outcomes:

  • High activity of TGF-β-SMAD signaling, which is regulated by TGFBR2 phosphorylation, was observed in aggressive glioblastomas and conferred poor prognosis in patients

  • Both SMAD-dependent and SMAD-independent signaling (via MAPK1/3) have been implicated in glioblastoma progression

• Functional studies in cancer models:

  • Inactivation of TGFBR2 led to increased self-renewal properties in glioblastoma cells

  • Autocrine production of TGF-β maintains stem cell-like properties through Sox2 expression, while also inducing differentiation of glioblastoma stem cells into pericytes to support tumor vessel function and growth

  • These contradictory responses to TGF-β signaling contribute to tumor heterogeneity in cancer stem cells

• Therapeutic targeting approaches:

  • Anti-TGFβRII monoclonal antibody LY3022859 has been evaluated in phase I clinical trials for patients with advanced solid tumors

  • Dose-limiting toxicities including infusion-related reactions and cytokine release syndrome were observed at doses of 1.25 mg/kg and 25 mg

  • The antibody demonstrated a short half-life (4.37–7.80 hours) and rapid clearance, with exposure increasing 2-fold when dose was increased from 12.5 mg to 25 mg

These findings highlight the complex role of TGFBR2 phosphorylation in cancer biology, suggesting that careful monitoring of phosphorylation status may provide valuable insights into tumor progression and response to therapy.

What role does TGFBR2 phosphorylation play in developmental disorders and genetic syndromes?

TGFBR2 phosphorylation plays a multifaceted role in developmental disorders and genetic syndromes, with particular significance in craniofacial and cardiovascular development:

• Genetic mutations affecting TGFBR2 phosphorylation:

  • Mutations in TGFBR2 have been associated with Marfan Syndrome, Loeys-Dietz Aortic Aneurysm Syndrome, and various types of tumors

  • These mutations often affect the protein kinase domain, which is critical for TGFBR2 function and phosphorylation events

  • A recent study investigated a TGFBR2 missense variant (V387M) in the context of cleft palate, though mouse model studies did not support its causality in craniofacial development disorders

• Developmental signaling pathway disruption:

  • TGFBR2 phosphorylation regulates receptor-ligand complex formation and subsequent phosphorylation of downstream proteins

  • These proteins enter the nucleus and regulate transcription of genes related to cell proliferation, differentiation, and migration during embryonic development

  • Disruption of these phosphorylation-dependent signaling cascades can lead to developmental abnormalities

• Experimental models for developmental disorders:

  • Research on TGFBR2 variants has employed genetic analysis and functional assessment in mouse models

  • For example, a V387M/V387M homozygous TGFBR2 mouse model was created to assess the role of this variant in craniofacial development

  • The lack of reduced survival or phenotypes reminiscent of human conditions in these mice suggests species-specific differences in TGFBR2 function

• Diagnostic applications of phospho-TGFBR2 antibodies:

  • Phospho-TGFBR2 (Ser225/250) antibodies can be utilized in research to analyze phosphorylation status in patient-derived samples

  • Immunohistochemistry applications for human brain tissue have been validated, demonstrating specific staining that can be blocked with phospho-peptides

  • This approach could potentially be extended to analyze samples from patients with suspected TGFBR2-related developmental disorders

Understanding the phosphorylation status of TGFBR2 in developmental contexts may provide critical insights into the pathophysiology of genetic syndromes and guide the development of targeted therapeutic approaches.

How is TGFBR2 phosphorylation involved in regulating stem cell properties and differentiation?

TGFBR2 phosphorylation plays a pivotal role in regulating stem cell properties and differentiation through multiple mechanisms:

• Regulation of stem cell self-renewal:

  • Research has demonstrated that inactivation of TGFBR2 leads to increased self-renewal properties in glioblastoma cells (GB2 cells)

  • This finding aligns with previous reports that TGFBR2-ablation in neural stem cells increases their capacity for sphere formation and self-renewal

  • The phosphorylation status of TGFBR2, particularly at sites like Ser225/250, likely mediates these effects by regulating downstream signaling pathways

• Control of differentiation pathways:

  • TGF-β signaling, mediated through phosphorylated TGFBR2, influences stem cell differentiation decisions

  • In glioblastoma, TGF-β can maintain stem cell-like properties through Sox2 expression while also inducing differentiation into pericytes

  • These contradictory responses contribute to tumor heterogeneity in cancer stem cells

• Integration with other signaling pathways:

  • Phosphorylated TGFBR2 activates both SMAD-dependent and SMAD-independent pathways

  • SMAD-independent signaling via MAPK1/3 has been linked to high expression of Nodal and cell proliferation in glioblastoma

  • The phosphorylation of key effector proteins like MAPK1 (Thr185/Tyr187) and MAPK3 (Tyr204) in serum-cultured GB2 cells aligns with previous findings regarding glioblastoma stem cells

• Experimental approaches to study phosphorylation in stem cells:

  • Quantitative phosphoproteomics combined with network analysis has successfully identified key signaling pathways in stem cell regulation

  • The kinase activity prediction based on phosphorylation sites, together with protein interaction-based upstream regulator analysis, highlighted TGFBR2-mediated signaling as a critical regulator of stem cell properties

  • Inhibition of TGFBR2 signaling experimentally validated these computational predictions

These findings suggest that monitoring and manipulating TGFBR2 phosphorylation may offer novel approaches to control stem cell fate in both normal development and disease contexts.

What are the best practices for quantitative analysis of TGFBR2 phosphorylation in various experimental systems?

Quantitative analysis of TGFBR2 phosphorylation requires rigorous methodological approaches to ensure accuracy and reproducibility:

• Western blot quantification:

  • Always run parallel blots for phospho-TGFBR2 (Ser225/250) and total TGFBR2

  • Normalize phospho-signal to total protein rather than housekeeping genes

  • Use recombinant phosphorylated standards for absolute quantification

  • Employ fluorescent secondary antibodies for wider linear dynamic range

  • Include phosphatase-treated controls to establish baseline

• ELISA-based quantification:

  • Utilize phospho-specific ELISA systems with validated antibody pairs

  • Develop standard curves using recombinant phosphorylated proteins

  • Implement phospho-ELISA that can detect specific phosphorylation at Ser225/250

  • Include appropriate controls to distinguish between phospho-immunogen and non-phospho-peptides

• Image-based quantification:

  • For immunohistochemistry or immunofluorescence, use automated pixel intensity analysis

  • Incorporate phospho-peptide blocking controls to confirm specificity

  • Apply cell segmentation algorithms for single-cell quantification

  • Quantify nuclear translocation of downstream effectors as functional readouts

• Mass spectrometry approaches:

  • Implement absolute quantification using isotope-labeled peptide standards

  • Analyze stoichiometry of phosphorylation at multiple sites

  • Apply kinase prediction algorithms to identify potential upstream regulators

  • Integrate with phosphoproteomic databases for comparative analysis

Research on TGFBR2 signaling in glioblastoma has successfully employed NetworKIN-based kinase prediction and IPA-guided upstream regulator determination, which was validated through targeted inhibition experiments. This integrated analytical approach uncovered the role of TGFBR2 in regulating stem cell-like properties .

How can I validate antibody specificity for phospho-TGFBR2 (Ser225/250) in my experimental system?

Validating antibody specificity for phospho-TGFBR2 (Ser225/250) is critical for generating reliable research data:

• Phosphopeptide competition assays:

  • Pre-incubate antibody with synthesized phosphopeptides corresponding to the Ser225/250 region

  • Compare immunoreactivity with and without peptide competition

  • Include non-phosphorylated peptide controls to verify phospho-specificity

  • Enzyme-linked immunosorbent assays (ELISA) can be used to demonstrate specific binding to phosphopeptides versus non-phosphopeptides

• Genetic validation approaches:

  • Generate TGFBR2 knockout cells using CRISPR/Cas9 or siRNA technologies

  • Create phospho-deficient mutants (S225A/S250A) through site-directed mutagenesis

  • Compare antibody reactivity across wild-type, knockout, and phospho-mutant samples

  • Rescue experiments with wild-type or mutant constructs provide additional validation

• Pharmacological validation:

  • Treat samples with phosphatase inhibitors to preserve phosphorylation

  • Compare with samples treated with serine/threonine phosphatases

  • Use specific TGF-β receptor kinase inhibitors to reduce phosphorylation

  • Stimulate with TGF-β ligands to increase receptor phosphorylation

• Cross-methodology validation:

  • Correlate Western blot results with immunohistochemistry findings

  • Compare antibody-based detection with mass spectrometry identification of phosphopeptides

  • Assess consistency across different tissue or cell types with known TGFBR2 expression profiles

Published research has demonstrated successful validation through immunohistochemistry analysis of paraffin-embedded human brain tissue, where specific staining could be blocked with the phospho peptide, confirming antibody specificity .

What are the critical considerations when comparing phospho-TGFBR2 data across different experimental platforms?

When comparing phospho-TGFBR2 data across different experimental platforms, researchers must address several critical considerations:

• Standardization of sample preparation:

  • Implement consistent protein extraction protocols across all platforms

  • Standardize phosphatase inhibitor cocktails to preserve phosphorylation status

  • Use identical stimulation protocols (timing, concentration) for TGF-β treatment

  • Process all samples simultaneously when possible to minimize batch effects

• Platform-specific limitations:

  • Western blotting: Semi-quantitative; limited by antibody specificity and linear dynamic range

  • Immunohistochemistry: Qualitative or semi-quantitative; affected by tissue fixation methods

  • Mass spectrometry: High specificity but variable sensitivity; requires specialized equipment

  • ELISA: Good quantitation but limited to specific epitopes and may lack spatial information

• Data normalization strategies:

  • For Western blots: Normalize phospho-signal to total protein rather than housekeeping genes

  • For immunohistochemistry: Use internal controls and standardized scoring systems

  • For mass spectrometry: Apply appropriate normalization to account for loading and ionization differences

  • For all platforms: Include common reference samples across experiments

• Integrated data analysis approaches:

  • Combine multiple detection methods for comprehensive phosphorylation assessment

  • Apply statistical methods appropriate for each platform's data characteristics

  • Use visualization tools that facilitate cross-platform comparisons

  • Implement machine learning algorithms for integrating multi-platform data

Research on TGF-β signaling in glioblastoma has successfully employed integrated bioinformatic analysis based on quantitative phosphoproteome data to systematically identify key signaling regulators. This approach combined phosphorylation site-oriented kinase prediction with protein interaction-based upstream regulator description to highlight the role of TGFBR2-mediated signaling .

What are the emerging research directions for TGFBR2 phosphorylation studies?

The field of TGFBR2 phosphorylation research is evolving rapidly, with several promising directions emerging:

• Single-cell phosphorylation analysis: New technologies enabling phosphoproteomic analysis at the single-cell level will allow researchers to investigate heterogeneity in TGFBR2 phosphorylation within tissues and tumors, providing unprecedented insights into signaling dynamics across diverse cell populations.

• Structural biology of phosphorylated receptors: Advanced structural studies using cryo-EM and X-ray crystallography are beginning to reveal how specific phosphorylation events, including at Ser225/250, induce conformational changes in TGFBR2 that alter its signaling properties and interactions with partner proteins.

• Systems biology integration: The integration of phosphorylation data with other -omics approaches (transcriptomics, metabolomics) through sophisticated computational modeling will provide comprehensive understanding of how TGFBR2 phosphorylation states influence broader cellular networks and phenotypic outcomes.

• Therapeutic targeting of specific phosphorylation states: Development of small molecules or biologics that selectively modulate specific TGFBR2 phosphorylation events, rather than general kinase inhibition, may offer more precise control over TGF-β signaling in disease contexts.

• Temporal dynamics of phosphorylation: Time-resolved phosphoproteomics of TGFBR2 signaling will reveal the sequence and interdependence of phosphorylation events, providing insights into signaling cascades that could be exploited therapeutically.